Pharmaceuticals, Biotechnology and Life Sciences
Aerie Pharmaceuticals has generated first quarter 2020 net revenues of $20.3 million, with net cash used in operating activities for the quarter ended March 31, 2020 on a U.S. GAAP basis totaled approximately $41.8 million, resulting in $264.7 million in cash and cash equivalents and investments as of March 31, 2020.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the first quarter with strong sales of Captisol to partners evaluating remdesivir in multiple clinical trials and scaling-up for potential treatment courses for COVID-19
“Growth strategies for big pharma companies are increasingly dependent on expansion into emerging markets,” says a market research analyst at Infiniti Research.
HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together…
another step forward for NBTXR3 activated by radiation therapy
Rocket Pharmaceuticals has reported a strong balance sheet with $275.9 million in cash, capitalized into 2022.
PinCell has added new members to its management team and the board of directors following a successful seed funding led by Sofinnova Partners
Transgene posts €35.3 million in cash and cash equivalents in Q1 2020, with minor impact from the Covid-19 pandemic seen to-date
DongWha Pharm’s said it is getting ready for second phase of clinical trials of new drug candidate DW2008 to treat COVID-19.
PHILADELPHIA–(BUSINESS WIRE)–Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell…